Creo Medical Share Discussion Threads

[dr biotech] 30/9/2024 15:03

I can't argue with that. Disappointing in multiple ways.

[peterrr3] 30/9/2024 14:58

Should have trusted my instincts and sold

[bmcollins] 30/9/2024 14:49

I just checked their website and nothing is showing as to when the HY announcement is due, but the AIM rules seem pretty clear that HY numbers are to be announced within 3 months of HY which still appears to be 30 June, meaning today should be the last day.
Very odd, unless they are going to come out after the close which would likely be ominous.

[cerrito] 30/9/2024 14:19

If the shares are suspended tomorrow as thr intetims have not been published, we will need a clear explanation as the reasons for the delay.

[dr biotech] 30/9/2024 09:26

Actual rules are 3months for interims, 4 months for finals. I have shares in MEGP. They once issued a "notice of results" and their results on the same day. Its wasnt a good look, but in their case the numbers were decent and it was all forgotten

I guess sorting out the MT deal would have taken a lot of time, and issuing an update would take a day or so if they were to publicise them - but having said that I didn't see a lot of PR for sale.

[peterrr3] 30/9/2024 07:36

Yup got to come out today doc

[dr biotech] 30/9/2024 06:49

My understanding is there is a maximum of 3 months from end of period to reporting. So I’m surprised there is no RNS this morning… does anyone know otherwise? I’m not 100% sure

[nimbo10] 28/9/2024 10:50

Mention in investors chronicle yesterday, don't have access.

[bjfanc] 27/9/2024 18:36

Probably doing the interims over the weekend. Guessing getting last week's deal done, took priority.

[dr biotech] 27/9/2024 10:49

I'm not sure if monday is the final cutoff, but thats the latest they have previously reported. Can't say I'm particularly optimistic given the languishing SP, but they are doing the right things in trying to show clinical superiority.

I'm guessing the sales of the non core products will be OK given that MT want to buy in. That should be in line. Sales of their own core products have probably been a bit slower than they would have liked - it may mean that they push back the timeline to breakeven. This will not be a disaster given the extended cash runway they will have. I guess some could interpret the 51% as a sign that it will take longer than planned. Of course they could prove me wrong and I'll be delighted if they do.

[bloomer2] 26/9/2024 14:10

I assume the share price is falling due to late 1st half results! When are these expected?

[peterrr3] 24/9/2024 21:07

Baillie Gifford Sep interview. Nothing new, but good explanation of the tech.https://www.bailliegifford.com/en/uk/individual-investors/insights/ic-article/2024-q3-trust-49-creo-medical-at-the-spearhead-of-surgery-10049581/

[peterrr3] 23/9/2024 19:07

I'm reasonably upbeat about the medium term as they have really ramped up the clinical training and sales teams in the US and there appears to be significant interest from Latin American training attendees. I expect some tough cash flow issues associated with the marketing push though, but then again Deutshe presumably asked about revenue before reiterating their buy recommendation.

[bmcollins] 23/9/2024 15:54

@Dr
It could be their vct (HHV)is selling, the last accounts, HY to 31 March show they held £771,000 of Creo which given the price end March seems to have been about 34p that would indicate a holding of about 2,250,000.if they are selling it would be a thumping loss, cost was £2.329m.
It would seem odd for the vct to sell at a loss though, especially as their Sep 2023 accounts showed the same holding as the Mar 2024 show, as their is a dearth of vct qualifying stocks to invest in,but it is at least an identifiable holding.
I would suspect it could well be their Marlborough fund though, as you suggested.

[nimbo10] 23/9/2024 15:20

Really is disappointing, the thrill of being on aim rollercaster ride.

Would like to know if there is an insti driving this down and if related to Pension funds having to liquidate to satisfy calls from holders driven by expected budget pension hits next month.

[dr biotech] 23/9/2024 15:11

I'm going to wait until the results, which will hopefully be in the next week. If that means I miss the bottom I'm comfortable with that and my exposure here is already high enough given its risk profile.

I don't see the reason for the fall, last weeks sale seemed to take away some uncertainty. I guess it may reduce margins in the future but only in the areas that they cover, and this should be more than covered by potential sales with the rest of MTs network.

If the seller is Cannacord I'd like to know their rationale. Concern as always is they know something we don't and as a 10% holder they should be closer to the company than us - but institutions don't hold forever, and if one of their clients wants to sell their funds that hold Creo they are forced sellers. I tried looking into which of their funds hold here but its not easy to find as its not sold to the public (but is probably their smaller companies fund).

[bmcollins] 23/9/2024 13:16

Nevertheless with that less than encouraging news under the belt I felt obliged to top up at under 27p this morning.
At these levels, & with a decent cash runway it looks to me like option money...

[peterrr3] 20/9/2024 18:45

The requests for preliminary data would have been in a few weeks and they are not in that group. I think the next round of review starting after that is next year so I reckon minimum Dec next year.They are finally looking at robot assisted surgery after millions of procedures and it being on the not yet list for years.

[dr biotech] 20/9/2024 16:38

In theory this was due after about 40 weeks, which would have been this march. However last time I heard this mentioned it hadn't moved off the drawing board due to NICE being understaffed. So unfortunately I think it will be a while.

You can see the latest here

hxxps://www.nice.org.uk/guidance/awaiting-development/gid-mt602

[nimbo10] 20/9/2024 16:33

Could do with positive NICE decision, isn't this due fairly soon?

[dr biotech] 20/9/2024 16:27

I'm generally against looking at single trades but there were 3 big sells at below the spread - I guess in a fairly illiquid stock that can be enough to move it. If cannacord or similar sold up then we will likely get an RNS next week.

Results should be soon, I'm guessing the distribution business will have done OK as otherwise they wouldn't have got the seemingly good price for it. The key area will be the core own products. I'm not expecting fireworks, a good linear progression with a promising outlook and perhaps some news on how the ablation trial is progressing.

I'm optomistic, but the lowly share price is a concern.

[nimbo10] 20/9/2024 16:09

The shareprice action is bemusing, are market makers just playing to catch out those that bought on the RNS? there isn't that much volume for such downward move. With normal transactions going down, MM see opportunities in increasing volumes with company RNS and swings in share price.

[bmcollins] 20/9/2024 14:28

@Dr
I agree, I'll see how it settles next week & look to pick a few more up again.
To me the rns could only be read as positive but that is AIM for you...

[1swifty] 20/9/2024 14:26

I worry there is a placing coming with the H1 release. Hope I'm wrong and it's nothing but positive news. Skeptic in me thinks release good news then achieve placing at higher share price Long term still very attractive